TACE联合瑞戈非尼及PD-1抑制剂二线治疗中晚期肝癌的疗效评价
Efficacy evaluation of TACE combined with regorafenib and PD-1 inhibitors as the second-line treatment for advanced liver cancer
范元媛 1朱帝文 1阿热阿勒·叶尔江 1李一帆 1任伟新1
作者信息
- 1. 830054 乌鲁木齐 新疆医科大学第一附属医院介入放射科
- 折叠
摘要
目的 探讨经动脉化疗栓塞(TACE)联合瑞戈非尼及PD-1 抑制剂二线治疗中晚期肝癌的疗效和不良反应.方法 收集 2018 年 12 月至 2024 年 4 月 49 例接受TACE联合瑞戈非尼及PD-1抑制剂或TACE联合瑞戈非尼作为二线治疗的中晚期HCC患者,其中 23 例接受TACE联合瑞戈非尼及PD-1抑制剂治疗,26 例接受TACE联合瑞戈非尼治疗.采用改良RECIST标准评价近期疗效.观察患者的近期疗效、远期疗效和不良反应.结果 TACE联合瑞戈非尼及PD-1 抑制剂组和TACE联合瑞戈非尼组的有效率分别为 34.8%和 15.4%(P>0.05),疾病控制率分别 73.9%和 46.2%(P<0.05),中位无进展生存期分别为 7 个月和 4 个月(P<0.05),中位总生存时间分别为 15 个月和 11 个月(P<0.05).两组主要不良反应为手足综合征、疲劳、发热和腹泻,以1～2 级为主,两组不良反应发生率的差异无统计学意义(P>0.05).结论 与TACE联合瑞戈非尼相比,TACE联合瑞戈非尼及PD-1抑制剂疗效更好,安全性可控.
Abstract
Objective To investigate the efficacy and adverse reactions of combined transarterial chemoembolization(TACE),regorafenib and PD-1 inhibitors as the second-line treatment for advanced hepatocellular carcinoma(HCC).Methods A total of 49 patients with advanced HCC who received TACE combined with regorafenib and PD-1 inhibitors or TACE combined with regorafenib as the second-line treatment from December 2018 to April 2024 were collected.Among them,23 patients received TACE combined with regorafenib and PD-1 inhibitors,and 26 patients received TACE combined with regorafenib.The modified RECIST criteria were used to evaluate the short-term efficacy.The patients'short-term efficacy,long-term efficacy,and adverse reactions were observed.Results The effective rates of TACE combined with regorafenib and PD-1 inhibitors and TACE combined with regorafenib were 34.8%and 15.4%(P>0.05),respectively.The disease control rates were 73.9%and 46.2%(P<0.05),respectively.The median progression-free survival was 7 months and 4 months(P<0.05),respectively.The median overall survival was 15 months and 11 months(P<0.05),respectively.The main adverse reactions in the both two groups were hand-foot syndrome,fatigue,fever and diarrhea,which were mostly of grade 1-2.There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Compared with TACE combined with regorafenib,TACE combined with regorafenib and PD-1 inhibitors has better efficacy and the safety is controllable.
关键词
肝细胞癌/经动脉化疗栓塞/瑞戈非尼/PD-1抑制剂/二线治疗Key words
Hepatocellular carcinoma/Transarterial chemoembolization/Regorafenib/PD-1 inhibitors/Second-line treatment引用本文复制引用
出版年
2024
NETL
NSTL
万方数据